These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 18580315)
1. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Brustmann H Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Brustmann H Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054 [TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
4. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Brustmann H Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981 [TBL] [Abstract][Full Text] [Related]
5. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer. Brustmann H Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250 [TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Brustmann H Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105 [TBL] [Abstract][Full Text] [Related]
7. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733 [TBL] [Abstract][Full Text] [Related]
8. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277 [TBL] [Abstract][Full Text] [Related]
11. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702 [TBL] [Abstract][Full Text] [Related]
12. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Cuatrecasas M; Catasus L; Palacios J; Prat J Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864 [TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Choi YL; Kim SH; Shin YK; Hong YC; Lee SJ; Kang SY; Ahn G Gynecol Oncol; 2005 May; 97(2):379-86. PubMed ID: 15863133 [TBL] [Abstract][Full Text] [Related]
14. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429 [TBL] [Abstract][Full Text] [Related]
15. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Weinberger PM; Adam BL; Gourin CG; Moretz WH; Bollag RJ; Wang BY; Liu Z; Lee JR; Terris DJ Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):503-10. PubMed ID: 17515507 [TBL] [Abstract][Full Text] [Related]
16. Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. Ferrazzo KL; Neto MM; dos Santos E; dos Santos Pinto D; de Sousa SO J Oral Pathol Med; 2009 Oct; 38(9):701-7. PubMed ID: 19659475 [TBL] [Abstract][Full Text] [Related]
17. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study. Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721 [TBL] [Abstract][Full Text] [Related]
18. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. Lin CK; Chao TK; Yu CP; Yu MH; Jin JS APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589 [TBL] [Abstract][Full Text] [Related]
19. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy. Wen YH; Yee H; Goswami S; Shukla PS Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814 [TBL] [Abstract][Full Text] [Related]
20. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma. Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]